You are using an outdated browser. Please upgrade your browser to improve your experience.



ARTIA™ RECONSTRUCTIVE TISSUE MATRIX is specifically designed for use in breast plastic and reconstructive surgeries.


WHAT IS ARTIA™ Reconstructive Tissue Matrix?

• A sterilized, surgical mesh that is derived from porcine skin, and is processed and preserved in a patented aqueous phosphate-buffered solution containing matrix stabilizers
• A tissue patch designed to reinforce soft tissue where weakness exists, and for the surgical repair of damaged or ruptured soft tissue membranes
• Provides for a strong and biocompatible implant that will incorporate into the patient’s tissue with associated cell and microvascular ingrowth


Product characteristics
• Pre-sterilized
• Does not require refrigeration—can be stored from -8°C–30°C
• Ready-to-use out of the package following a 2-minute soak in sterile saline or lactated Ringer’s solution
• Once opened and retained in sterile solution, must be used within 4 hours


Perforated options designed to:
• Allow fluid to flow through matrix
• Support tissue ingrowth
• Incorporate a 1.2 cm space around the perimeter of the perforation pattern in each piece to avoid suturing interference


Contoured shape options specifically designed for breast reconstruction, and designed to:
• Reduce time for product trimming
• Make intraoperative placement easier and more predictable

How it works

Clinical results
In a short-term safety profile evaluating the outcomes following the use of ArtiaTM in consecutive immediate implant-based breast reconstruction in 17 patients

• There were no implant losses (mean follow up of 177 days), compared with over 9% identified in an audit for the Implant Breast Reconstruction evAluation (IBRA) study
• Artia™ appeared to provide an effective, functional, reconstructive matrix with a generally good safety profile when utilised for either therapeutic or prophylactic mastectomy with implant reconstruction
• Investigators stated they associated Artia™ with minimal post-operative complications and good patient satisfaction


Outcome data in patients who had received Artia™-assisted breast reconstruction was compared to patients recipient of other ADMs such as Strattice™ or Surgimend™

• Artia™ was used in 31 patients undergoing 51 implant-based breast reconstructions between July 2016 and August 2017
• The overall complication rate was 9.8% with reports of complications in 5 breasts from 4 patients (mean follow-up of 171 days)
• Minor complications: 3 cases of seromas which were drained in the post-operative clinic appointment
• Major complications: 1 patient suffered bilateral implant losses following infection and skin necrosis
• No delays to adjuvant treatment in therapeutic cases
• Complication rates compared with those of well-established ADMs such as Strattice™, Surgimend™ and AlloDerm™ from literature



Video instructions

Cookie and Privacy Statement

We use cookies to improve the functionality of our website. The data is collected completely anonymously..Want to know more? Check our Cookie and Privacy Statement